Plus   Neg

Tetraphase Pharmaceuticals (TTPH) Is Sinking After Phase 3 Study Fails

Tetraphase Pharmaceuticals (TTPH) announced after the close Tuesday that its Phase 3 study of once-daily intravenous eravacycline compared to ertapenem for the treatment of patients with complicated urinary tract infections did not achieve it co-primary endpoints.

Tetraphase Pharmaceuticals has gapped open sharply lower Wednesday morning and is now down 3.04 at $2.39 with volume at over a 6-month high. The stock has tumbled to a new low for the year.

For comments and feedback contact: editorial@rttnews.com

Business News

$5 And Under

0 Articles
Follow RTT